GlassScriptPhysician profile
Maria C Abeleda
NPI 1871554907
$8,441.76
in general payments reported to CMS, 2019-2025
19 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $824 · 2021: $1,143 · 2022: $1,121 · 2023: $1,681 · 2024: $1,397 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,854 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,853.87 |
| Education | $334.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,696.50 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,617.79 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $985.05 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $874.28 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $668.42 | 2019-2025 | Ingrezza |
| Abbvie INC. | $574.78 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $538.06 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $352.67 | 2024-2025 | Cobenfy |
| Allergan, INC. | $348.75 | 2019-2020 | |
| Lundbeck LLC | $205.01 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $183.77 | 2020-2025 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $116.58 | 2019 | |
| Axsome Therapeutics, INC. | $84.14 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $69.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $24.92 | 2024 | Lucemyra |
| Corium, LLC | $21.94 | 2023 | Azstarys |
| Indivior INC. | $16.03 | 2024 | Perseris |
| Merck Sharp & Dohme LLC | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Abeleda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.